CCL11: Eotaxin
Chemokine that plays a central role in both allergic and non- allergic inflammatory reactions by inducing the migration of different leukocyte types including eosinophils, basophils, macrophages and dendritic cells.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CCL11, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Bertilimumab | Phase 2 | AstraZeneca Pharmaceuticals | Antibody | InhibitorEotaxin inhibitor | 0 |
- Inflammatory bowel disease0.31
- Hyperpituitarism0.23
- Apnea0.23
- Vertebral column disorder0.22
- Psoriasis0.18
- Abnormality of the skeletal system0.17
- Sinusitis0.16
- Lagophthalmos0.16
- Acute tonsillitis0.15
- Alcohol drinking0.14
- Hodgkins lymphoma0.14
- Crohn disease0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3286077, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P51671, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets